Dohj LLC Takes $377,000 Position in Danaher Co. (NYSE:DHR)

Dohj LLC bought a new stake in shares of Danaher Co. (NYSE:DHR) during the 4th quarter, according to its most recent filing with the SEC. The fund bought 1,630 shares of the conglomerate’s stock, valued at approximately $377,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Wellington Management Group LLP increased its holdings in shares of Danaher by 18.6% during the third quarter. Wellington Management Group LLP now owns 24,930,281 shares of the conglomerate’s stock worth $6,185,203,000 after buying an additional 3,905,449 shares in the last quarter. Allen Investment Management LLC increased its holdings in Danaher by 1,440.7% during the 3rd quarter. Allen Investment Management LLC now owns 1,100,399 shares of the conglomerate’s stock valued at $273,009,000 after purchasing an additional 1,028,976 shares in the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new position in Danaher in the 3rd quarter valued at $178,850,000. Alecta Tjanstepension Omsesidigt acquired a new position in Danaher in the fourth quarter worth $161,994,000. Finally, Harris Associates L P grew its holdings in shares of Danaher by 27.7% during the third quarter. Harris Associates L P now owns 2,963,899 shares of the conglomerate’s stock worth $735,343,000 after purchasing an additional 642,759 shares during the last quarter. Institutional investors own 79.05% of the company’s stock.

Insiders Place Their Bets

In related news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction dated Tuesday, February 13th. The shares were sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at approximately $1,029,891.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other news, SVP Georgeann Couchara sold 2,622 shares of Danaher stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $242.67, for a total transaction of $636,280.74. Following the completion of the sale, the senior vice president now owns 4,244 shares of the company’s stock, valued at $1,029,891.48. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Daniel Raskas sold 23,757 shares of the stock in a transaction that occurred on Monday, February 26th. The stock was sold at an average price of $252.00, for a total transaction of $5,986,764.00. Following the transaction, the senior vice president now owns 38,102 shares in the company, valued at approximately $9,601,704. The disclosure for this sale can be found here. Insiders sold a total of 106,565 shares of company stock valued at $26,641,364 over the last ninety days. 11.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on DHR shares. TD Cowen lifted their target price on Danaher from $280.00 to $290.00 and gave the company a “buy” rating in a research note on Wednesday. StockNews.com downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research report on Wednesday, January 31st. Barclays raised their target price on shares of Danaher from $260.00 to $270.00 and gave the company an “equal weight” rating in a research note on Wednesday. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price target for the stock from $250.00 to $280.00 in a research note on Wednesday, April 17th. Finally, Raymond James raised their price objective on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Six analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $270.00.

Danaher Stock Up 0.3 %

Shares of DHR stock traded up $0.78 during trading on Friday, reaching $246.58. The company’s stock had a trading volume of 2,710,446 shares, compared to its average volume of 2,710,897. The company has a market cap of $182.64 billion, a price-to-earnings ratio of 41.77, a price-to-earnings-growth ratio of 3.78 and a beta of 0.83. Danaher Co. has a one year low of $182.09 and a one year high of $259.00. The business has a fifty day moving average price of $248.87 and a 200-day moving average price of $231.08. The company has a quick ratio of 1.37, a current ratio of 1.85 and a debt-to-equity ratio of 0.31.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. The firm had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business’s revenue was down 2.6% compared to the same quarter last year. During the same period last year, the company earned $2.36 earnings per share. Analysts anticipate that Danaher Co. will post 7.65 earnings per share for the current year.

Danaher Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Friday, April 26th. Investors of record on Thursday, March 28th were paid a $0.27 dividend. This represents a $1.08 dividend on an annualized basis and a yield of 0.44%. The ex-dividend date of this dividend was Wednesday, March 27th. This is a boost from Danaher’s previous quarterly dividend of $0.24. Danaher’s dividend payout ratio is 18.31%.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.